• Home
  • About NMSG
  • NMSG Membership
  • NMSG Fellowship
  • NMSG Shark Tank
  • Meetings
    • 2026 NMSG Scientific Meeting
    • 2026 NMSG Meeting Abstract Submission
    • Upcoming NMSG Meetings
    • NMSG Meetings Archive
    • Other Neuromuscular Meetings
  • Resources
    • Publications
    • Clinical Trials
Skip to content
Neuromuscular Study Group
  • Home
  • About NMSG
  • NMSG Membership
  • NMSG Fellowship
  • NMSG Shark Tank
  • Meetings
    • 2026 NMSG Scientific Meeting
    • 2026 NMSG Meeting Abstract Submission
    • Upcoming NMSG Meetings
    • NMSG Meetings Archive
    • Other Neuromuscular Meetings
  • Resources
    • Publications
    • Clinical Trials
msg-admin

Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis (Rasagiline)

Posted on April 7, 2016 by msg-admin

This entry was posted in Completed and tagged . Bookmark the permalink.
Post navigation
← Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find the Optimum Steroid Regimen (FOR-DMD)
Using Next Generation Sequencing to Unravel the Pathogenesis of Sporadic Inclusion Body Myositis →

Contact Us

Donna Schwartze

Elizabeth Russo Paulk

Privacy Policy

Admin Login

Site Search

Sign up for our newsletter

Select list(s) to subscribe to

By submitting this form, you are consenting to receive marketing emails from the Neuromuscular Study Group. You can revoke your consent at any time by using the SafeUnsubscribe® link found at the bottom of every email. Emails are serviced by Constant Contact.

© The Neuromuscular Study Group Inc. All rights reserved. Site by Academic Web Pages

Back to Top